Daridorexant (Quviviq) Versus Ramelteon (Rozerem) Efficacy for Insomnia in Adults
Direct, randomized head-to-head efficacy trials comparing daridorexant with ramelteon were not identified in the cited evidence base. [1]
Indirect comparative efficacy evidence supports greater hypnotic efficacy of daridorexant than ramelteon, with ramelteon showing small or limited effects on sleep parameters. [1], [2], [3]
Evidence Base for Comparative Efficacy
Direct Head-to-Head Trials
No randomized trials directly comparing daridorexant with ramelteon for insomnia in adults were identified in the cited network evidence. [1]
Indirect Comparative Efficacy Signal
A large network meta-analysis concluded that licensed drugs including daridorexant can be effective for acute insomnia treatment, while melatonin receptor agonists including ramelteon did not show overall material benefits. [1]
Efficacy of Daridorexant
In a systematic review and meta-analysis of randomized placebo-controlled trials, daridorexant 50 mg improved multiple subjective and objective sleep outcomes versus placebo at month 1, including polysomnography-measured wake after sleep onset (WASO) and subjective time to sleep onset (LPS), as well as subjective total sleep time and insomnia-related symptom scales. [2]
Reported effect sizes for daridorexant versus placebo at month 1 included: WASO standardized mean difference (SMD) −0.62 (95% CI −0.85 to −0.39), LPS SMD −0.36 (95% CI −0.50 to −0.21), subjective total sleep time (SMD 0.45, 95% CI 0.31 to 0.60), and insomnia sleepiness domain score (SMD −0.37, 95% CI −0.53 to −0.21). [2]
Efficacy of Ramelteon
In a systematic review and meta-analysis of randomized placebo-controlled trials, ramelteon was associated with reduced subjective sleep latency (sSL) and improved sleep quality, with no associated increase in subjective total sleep time (sTST). [3]
Reported effect sizes for ramelteon versus placebo included: sleep quality standardized mean difference −0.074 (95% CI −0.13 to −0.02). [3]
Comparative Interpretation for Adults With Insomnia
The network meta-analysis indicated that ramelteon did not show overall material benefit while daridorexant was included among medications that can be effective for acute insomnia. [1]
The magnitude of sleep-quality improvement reported for ramelteon versus placebo (SMD −0.074) was small, whereas daridorexant demonstrated larger effect sizes across multiple sleep domains in placebo-controlled trials. [2], [3]
Guideline Positioning (Efficacy Strength)
The American Academy of Sleep Medicine guideline assigned weak evidence of efficacy for sleep onset insomnia with ramelteon. [4]
The American Academy of Sleep Medicine guideline supports pharmacologic therapy that includes orexin receptor antagonists for insomnia based on trial efficacy data, consistent with the larger placebo-controlled efficacy effects reported for daridorexant. [4]
Practical Efficacy Summary for Decision-Making
For adult insomnia, daridorexant shows larger placebo-associated improvements in sleep measures than ramelteon, while ramelteon shows small effects limited largely to sleep-onset domains and may not demonstrate overall material benefit. [1], [2], [3]
Common clinical implication is that expected efficacy for sleep-onset and global insomnia symptom improvement is higher with daridorexant than with ramelteon. [1], [2], [3]
Key Quantitative Effects Used for Comparison
- Daridorexant 50 mg versus placebo (month 1): WASO SMD −0.62; LPS SMD −0.36; subjective total sleep time SMD 0.45; sleepiness domain score SMD −0.37. [2]
- Ramelteon versus placebo: sleep-quality SMD −0.074. [3]